With the experimental Ebola drug ZMapp arriving in Liberia, the country faces the tough choice of choosing the handful number of Ebola patients who will receive the drug that could prove either life-saving or life-threatening.

Twelve doses of the untested Ebola drug, being developed by Mapp Biopharmaceuticals, arrived in the West African country late yesterday.

According to the reports, Liberia's Minister of Foreign Affairs, Augustine Ngufuan, is said to have couriered the two boxes of Zmapp himself on a commercial flight from the U.S. to Monrovia, where it was unloaded at a VIP terminal.

The assistant health minister Tolbert Nyenswah has confirmed that three or four people would be getting it today and the government has confirmed that two doctors will receive the treatment, but it is still unclear who would get the experimental treatment.

It should be noted that these are the last known doses of ZMapp left in the world. Mapp Biopharmaceuticals, the US-based company that is involved with the development of the drug has said it will take months to build up even a modest supply. The testing of the drug in West Africa has sparked a debate over the ethical conduct of administering drugs that have not yet been tested for safety or efficacy to the sick.

The recent West Africa's Ebola virus outbreak has overwhelmed the region's already strained health systems. The charity group Doctors Without Borders, which is running many of the Ebola treatment centres and whose staff have tussled with whether to provide ZMapp, said such choices present 'an impossible dilemma'.

Liberian officials have confirmed that the first Liberian patients expected to be given Zmapp will be Zukunis Ireland and Abraham Borbor, two doctors who caught Ebola virus while treating patients. 'The criteria of selection is difficult, but it is going to be done,' said Dr Moses Massaquoi, who helped Liberia obtain the drug from Mapp Biopharmaceutical.